FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224433847> ?p ?o ?g. }

• W4224433847 endingPage "118" @default.
• W4224433847 startingPage "110" @default.
• W4224433847 abstract "The clinical use of androgen receptor (AR) antagonists has been successful in treating prostate cancer patients, inducing remission of androgen-dependent tumors. However, a couple of years after treatment, prostate tumors transition into an androgen-independent state with altered gene expression profiles, but the molecular basis is not understood. Since the AR antagonists trigger this transition, we assessed whether AR antagonists induce chromatin reorganization in an androgen-dependent prostate cancer cell line (LNCaP). Treatment of LNCaP cells with two clinically used AR antagonists (bicalutamide [Bic] and enzalutamide [Enz]) expectedly resulted in antagonistic effects on cell proliferation, AR transactivation, and dihydrotestosterone (DHT)-induced expression of AR target genes. Thus, the antagonists expectedly acted to antagonize the transactivation function of AR activated by androgen binding. By ChIP-qPCR assay, AR bound to Bic, but not Enz, was recruited to an endogenous consensus AR-binding site within the kallikrein-related peptidase 3 gene promoter after treatment with Bic, similar to the effect of DHT. By ATAC-seq analysis of the cells after long-term treatment for 5 days, Bic and dihydrotestosterone DHT induced different chromatin reorganization patterns and gene expression profiles, suggesting that Bic exhibited a distinct action from that by DHT. Thus, these results suggest that the action of a known AR antagonist is mediated by chromatin reorganization in a prostate cancer cell line." @default.
• W4224433847 created "2022-04-27" @default.
• W4224433847 creator A5003483247 @default.
• W4224433847 creator A5003797388 @default.
• W4224433847 creator A5022828101 @default.
• W4224433847 creator A5027044231 @default.
• W4224433847 creator A5040328741 @default.
• W4224433847 creator A5055994703 @default.
• W4224433847 creator A5091288465 @default.
• W4224433847 date "2022-07-01" @default.
• W4224433847 modified "2023-09-30" @default.
• W4224433847 title "Antagonistic action of a synthetic androgen ligand mediated by chromatin remodeling in a human prostate cancer cell line" @default.
• W4224433847 cites W1531821806 @default.
• W4224433847 cites W1968126063 @default.
• W4224433847 cites W1975715657 @default.
• W4224433847 cites W1994644909 @default.
• W4224433847 cites W2009858080 @default.
• W4224433847 cites W2014686801 @default.
• W4224433847 cites W2015845481 @default.
• W4224433847 cites W2033152023 @default.
• W4224433847 cites W2041825762 @default.
• W4224433847 cites W2055296531 @default.
• W4224433847 cites W2089518544 @default.
• W4224433847 cites W2092515164 @default.
• W4224433847 cites W2099460616 @default.
• W4224433847 cites W2114448119 @default.
• W4224433847 cites W2117757143 @default.
• W4224433847 cites W2117965089 @default.
• W4224433847 cites W2122683221 @default.
• W4224433847 cites W2126068460 @default.
• W4224433847 cites W2127996002 @default.
• W4224433847 cites W2136180772 @default.
• W4224433847 cites W2148643283 @default.
• W4224433847 cites W2164236134 @default.
• W4224433847 cites W2166037178 @default.
• W4224433847 cites W2172256092 @default.
• W4224433847 cites W2342608812 @default.
• W4224433847 cites W2404460725 @default.
• W4224433847 cites W2610160407 @default.
• W4224433847 cites W2782193891 @default.
• W4224433847 cites W2802285866 @default.
• W4224433847 cites W2966112499 @default.
• W4224433847 cites W3112289427 @default.
• W4224433847 cites W3186413462 @default.
• W4224433847 cites W4205718372 @default.
• W4224433847 cites W4211087830 @default.
• W4224433847 doi "https://doi.org/10.1016/j.bbrc.2022.04.109" @default.
• W4224433847 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35523048" @default.
• W4224433847 hasPublicationYear "2022" @default.
• W4224433847 type Work @default.
• W4224433847 citedByCount "3" @default.
• W4224433847 countsByYear W42244338472022 @default.
• W4224433847 countsByYear W42244338472023 @default.
• W4224433847 crossrefType "journal-article" @default.
• W4224433847 hasAuthorship W4224433847A5003483247 @default.
• W4224433847 hasAuthorship W4224433847A5003797388 @default.
• W4224433847 hasAuthorship W4224433847A5022828101 @default.
• W4224433847 hasAuthorship W4224433847A5027044231 @default.
• W4224433847 hasAuthorship W4224433847A5040328741 @default.
• W4224433847 hasAuthorship W4224433847A5055994703 @default.
• W4224433847 hasAuthorship W4224433847A5091288465 @default.
• W4224433847 hasConcept C101762097 @default.
• W4224433847 hasConcept C104317684 @default.
• W4224433847 hasConcept C121608353 @default.
• W4224433847 hasConcept C126322002 @default.
• W4224433847 hasConcept C1292079 @default.
• W4224433847 hasConcept C134018914 @default.
• W4224433847 hasConcept C134320426 @default.
• W4224433847 hasConcept C150194340 @default.
• W4224433847 hasConcept C185592680 @default.
• W4224433847 hasConcept C2776551883 @default.
• W4224433847 hasConcept C2777911890 @default.
• W4224433847 hasConcept C2779322244 @default.
• W4224433847 hasConcept C2779723316 @default.
• W4224433847 hasConcept C2779881493 @default.
• W4224433847 hasConcept C2780192828 @default.
• W4224433847 hasConcept C2780962315 @default.
• W4224433847 hasConcept C502942594 @default.
• W4224433847 hasConcept C54355233 @default.
• W4224433847 hasConcept C61367390 @default.
• W4224433847 hasConcept C71315377 @default.
• W4224433847 hasConcept C71924100 @default.
• W4224433847 hasConcept C86339819 @default.
• W4224433847 hasConcept C86803240 @default.
• W4224433847 hasConceptScore W4224433847C101762097 @default.
• W4224433847 hasConceptScore W4224433847C104317684 @default.
• W4224433847 hasConceptScore W4224433847C121608353 @default.
• W4224433847 hasConceptScore W4224433847C126322002 @default.
• W4224433847 hasConceptScore W4224433847C1292079 @default.
• W4224433847 hasConceptScore W4224433847C134018914 @default.
• W4224433847 hasConceptScore W4224433847C134320426 @default.
• W4224433847 hasConceptScore W4224433847C150194340 @default.
• W4224433847 hasConceptScore W4224433847C185592680 @default.
• W4224433847 hasConceptScore W4224433847C2776551883 @default.
• W4224433847 hasConceptScore W4224433847C2777911890 @default.
• W4224433847 hasConceptScore W4224433847C2779322244 @default.
• W4224433847 hasConceptScore W4224433847C2779723316 @default.
• W4224433847 hasConceptScore W4224433847C2779881493 @default.

• next